GlassScriptPhysician profile
Parul S Jani
NPI 1174527501
$13,596.45
in general payments reported to CMS, 2019-2025
52 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,512 · 2020: $1,427 · 2021: $2,370 · 2022: $1,293 · 2023: $1,992 · 2024: $1,875 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,994.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,616.59 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Amgen INC. | $1,556.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $1,005.48 | 2020-2025 | |
| Novo Nordisk INC | $987.17 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $929.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $710.22 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $644.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $577.81 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $459.95 | 2019-2025 | Mounjaro, Jardiance |
| Esperion Therapeutics, INC. | $430.58 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $396.99 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $382.29 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $329.15 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $251.71 | 2019-2025 | Veozah |
| Allergan, INC. | $228.14 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.